ABSTRACT
INTRODUCTION
Adoptive T cell transfer after host preconditioning by lymphodepletion represents an important advance in cancer immunotherapy (June, 2007b; Schumacher and Restifo, 2009) , and CD4 + T cells have been identified as potent effectors of this approach (Radfar et al., 2009 ). However, successful adoptive CD4 + T cell based clinical trials are limited (Gattinoni et al., 2006) . The major obstacles to achieving satisfactory therapeutic outcomes include (1) the isolation and expansion of tumor-specific CD4 + T cells are not successful and (2) the prolonged ex vivo T cell expansion process with recombinant IL-2 may result in CD4 + T cells reaching replicative senescence (June, 2007a; Leen et al., 2007) . Development of strategies to overcome these restrictions could significantly improve the clinical outcome of patients receiving adoptive CD4 + T cell therapy.
The efficacy of adoptive T cell transfer is enhanced by other immunotherapy methods, such as the administration of cytokines (Leen et al., 2007) . As an important T cell growth factor, IL-15 has been demonstrated to prolong the persistence of adoptively transferred cytotoxic T cells (CTLs) in vivo (Quintarelli et al., 2007) . The major effects of IL-15 on T cells include (1) enhanced cytotoxic ability and proliferation of CTLs in vivo (Klebanoff et al., 2004) , (2) activation of the telomerase and elongation of telomeres (Li et al., 2005) , (3) ability to rescue tumor-tolerant T cells for use in adoptive immunotherapy (Teague et al., 2006) , and (4) inhibition of activation-induced cell death of T cells (Marks-Konczalik et al., 2000) . However, whether and how IL-15 treatment could enhance the anti-tumor activity of adoptively transferred CD4
The development of retrovirus vectors has increased the efficiency of T cell engineering (Sharma et al., 1996) . Moreover, it has been reported that retrovirus vectors carrying T cell receptors may confer T cell a specific ability to recognize tumors and these engineered T cells could mediate cancer regression in melanoma patients (Abad et al., 2008) . It is well know that retrovirus vectors only engineer proliferative T cells (Culver et al., 1992) and thus, tumor specific T cells should be selectively engineered under a condition where these cells are specifically stimulated to proliferate with tumor antigens.
The generation of tumor-specific CD4 + T cells is often a limitation, because the intrinsic population of tumor reactive CD4 + T cells in patients is extremely small and OKT3 mediated or repeated antigen-pulse proliferation may lead to apoptosis in the tumor-reactive CD4 + T cells (Muranski and Restifo, 2009 ). Developing optimal cell culture systems with the ability to expand antigen-specific CD4 + T cells is extremely urgent. In this report, an MLV-based retroviral vector pTK-IL15 encoding both human IL-15 and thymidine kinase (a wellknown suicide gene) was constructed. Thymidine kinase was used to help eliminate IL-15 transfected CD4 + T cells in order to avoid possible T lymphoma or autoimmune diseases. The results demonstrated that retrovirus-mediated IL-15 expression may represent an optimal cell expansion system with the capacity to generate large amount of tumor-specific CD4 + T cells and enhance their anti-tumor activity in vivo.
RESULTS

Construction of IL-15 expression retroviral vector
The retroviral vectors, containing either the "suicide" herpes simplex virus thymidine kinase gene alone (pTK-Con) or together with the human IL-15 gene (pTK-IL15) or the green fluorescent protein gene (pTK-GFP) were constructed according to the schema as shown in Fig. 1A . The CD4 + T cells from Tcell receptor (TCR) transgenic mice Do11.10 were activated with the specific antigen ovalbumine and transfected subsequently with the retroviral vectors described above. Intracellular IL-15 is reported to participate in signal transduction (Bergamaschi et al., 2008) . Figure 2A shows as a result of the low transduction efficiency; (2) some CD4 + T cells transfected with pTK-IL15 did not express membranebound IL-15 even if the transfection efficiency of retroviral vector was not low. To resolve this problem, CD4 + T cells were transfected with pTK-GFP retroviral vector to determine the transfection efficiency. As shown in Fig. 2C , the proportion of GFP positive CD4 + T cells after transfection with a MOI of 1 was 8.16% (namely 7.2%± 1.5%), indicating that the transfection efficacy was relatively low under this condition. Since the transfection efficiency could be improved (data not shown) and the low transfection efficiency with a MOI of 1 had significant biological effects, most of the experiments of retroviral vector transfection were done following above protocol. However, the exact efficacy of pTK-IL15 transfection on proliferation of CD4 + T cells is still not known. To resolve this problem, the transfected CD4 + T cells were cultured with recombinant hIL-2 (10 ng/mL) after retroviral vector transfection and the quantity of CD4 + T cells was determined by cell counting (Fig. 3A) or an MTT assay (Fig. 3B) Figure 5C shows that pTK-IL15 transfection dramatically decreased the apoptotic percentage of CD4 + T cells from 27% to 14% compared to pTK-Con transfection. Recombinant hIL-2 did not abrogate the anti-apoptotic effect of pTK-IL15, and the apoptotic percentage of CD4 + T cells decreased from 32% to 16% (Fig. 5D ). Retrovirus mediated IL-15 expression was demonstrated to inhibit the apoptosis of CD4 + T cells to ensure the expansion dominance of pTK-IL15 transfected CD4 + T cells.
Prolonged survival of pTK-IL15 transfected CD4 + T cells in vivo
The pTK-IL15 transfection selectively expands antigenspecific CD4 + T cells in vitro. To follow the fate of such cells in vivo, pTK-IL15 transfected Do11.10 T cells were adoptively transferred into TSA-mOva bearing mice and traced by using specific mAbs against KJ26 and CD4 . As shown in Fig. 6A , three days after T cell infusion, the proportion of pTK-IL15 transfected CD4 + T cells was higher Fig. 8A ; p < 0.05), and efficiently prolonged the survival of tumor-bearing mice (Fig. 8B) . Similar results were obtained in the J558L-mOva plasmacytoma model ( Fig. 8C and 8D ; p < 0.05). These findings suggested that pTK-IL15 transfection enhanced the antitumor effect of CD4 + T cells. gene thymidine kinase (TK) was used to modify T cells (Black et al., 1996) . In the J558-mOva tumor model, tumor growth was completely suppressed after infusion of pTK-IL15 transfected T cells in partial experimented animals. And these mice had been monitored for another 15 months and no T lymphoma was observed. To be sure that ganciclovir (GCV) could eliminate pTK-IL15 transfected CD4 + T cells in vivo, 15 mg/kg GCV was injected once a day for 3 days after T cells infusion. Our results proved that GCV treatment efficiently eliminated both pTK-IL15 transfected CD4 + T cells and pTKCon transfected CD4 + T cells in vivo ( Fig. 9A and 9B ). This enhances the safety of using pTK-IL15 transfected CD4 + T cell in clinical therapy.
DISCUSSION
For the first time, we demonstrated here that retrovirus mediated IL-15 expression induced a selective expansion of antigen-specific CD4 + T cells ex vivo and enhanced their tumor-suppression effect in vivo. This finding may have important significance for the improvement of T cell therapy against cancer.
Major obstacles for efficient adoptive T cell therapy are: (1) the difficulty in preparing enough tumor-specific T cells over a short time (Schumacher and Restifo, 2009) and (2) 
2005
). There are currently no forms of FDA-approved T cell therapy available for cancer, because no randomized clinical trials have been able to demonstrate the anti-tumor efficacy of adoptive T cell therapy for cancers other than melanoma (June, 2007a) .
To ensure the source of the adoptively transferred T cells, two major strategies have emerged: naturally-occurring T cells and TCR/CAR (chimeric antigen receptor) genetically engineered T cells (Cox et al., 1994; Dunbar et al., 1999; Schumacher, 2002) . For the first strategy, tumor-reactive T cells are scarce in cancer patients, and repetitive antigenpulse leads to the apoptosis of tumor-reactive T cells. Thus, the generation of T cell lines and T cell clones is a long and cumbersome process (Disis et al., 2002) . Therefore, optimization of protocols for generation of tumor-reactive T cells for adoptive cell therapy is essential.
In this study, pTK-IL15 retroviral vector was used to enhance the antigen-specific CD4 + T cell expanding effi- physiological condition, membrane-bound IL-15 is not detected unless IL-15 and IL-15Rα are coordinately expressed by the same immune cells (Burkett et al., 2004) . Naturally, CD4 + Tcells express IL-15Rα but not IL-15 and hold no membrane-bound IL-15 (Cosman et al., 1995) . Therefore, upon retroviral modification, the CD4 + T cells express both soluble and membrane-bound IL-15. These lead to enhanced expansion of gene-modified T cells as well as bystander cells such as CTLs and NK cells. Secondly, retrovirus mediated IL-15 expression induced a selective expansion of antigen-specific CD4 + T cells. The retroviral vector selectively transfects the proliferating cells (Culver et al., 1992 , a large number of non-specific T cells received IL-15 signal from pTK-IL15 transfected antigen-specific T cells. The increase in non-specific CD4 + T cells was proportional to the increase in antigen-specific CD4 + T cells. Besides, the number of non-specific T cells was far greater than antigenspecific T cells in dilution ratios of 1:10 4 to 1:10 6 . The increase of non-specific CD4 + T cells was insignificant (Fig. 4) .
Fortunately, natural tumor-specific CD4 + T cells present at very low frequencies and the frequency of tumor-specific CD4 + T cells in responding melanoma patients ranged from 0.0037% to 0.080% with a median of 0.024% of the CD4 + cell population (Ladekarl et al., 2004) . So the dilution ratios of 1:10 4 -1:10 6 are rational but ratios of 1:10 2 -1:10 3 are not.
Moreover, fewer pTK-IL15 transfected CD4 + T cells would express less soluble IL-15 and membrane-bound IL-15. So these cells would not induce severe side effect in vivo. Thirdly, pTK-IL15 transfected CD4 + T cells efficiently suppressed tumor growth in vivo (Fig. 8) . Tumor-specific CD4 + T cells perform anti-tumor effect through multiple mechanisms: (1) CD4 + T cells directly recognize and eliminate MHCII-positive tumor cells (Quezada et al., 2010; Xie et al., 2010) ; (2) CD4 + T cells secrete IFN-γ to inhibit the angiogenesis and suppress the growth of tumor (Qin and Blankenstein, 2000) ; (3) CD4 + T cells promote the proliferation, activation and maturation of CTLs, NK cells and macrophages to enhance the anti-tumor immune responses (Toes et al., 1999; Cohen et al., 2000) . IL-15 transduction prolonged the survival of antigen-specific CD4 + T cells in vivo.
These in turn activated CTLs, NK cells and macrophages to enhance multiple anti-tumor reactions.
Finally, IL-15 retroviral vector carries suicide gene to ensure the clinical safety. In our model, adoptive pTK-IL15 transfected T cells mainly bear two aspects of adverse effect: (1) Infused CD4 + T cells damage the normal tissue. Partial T cells used in adoptive T cell therapy recognize the tumorassociated antigen but not tumor-specific antigen, which means normal tissues could not avoid being injured (Phan et al., 2003) . For example, vitiligo occurred in some melanoma patients receiving adoptive T cell therapy (Dudley et al., 2002) . (2) Retrovirus vector modification may induce insertion mutation and lead to T lymphoma. To avoid above side effects, TK was constructed into retroviral vector and GCV treatment could efficiently eliminate the cells expressing TK.
As a chemical drug, GCV has been used in phase III clinical trials and holds no obvious adverse reaction to patients (Rainov, 2000) . Importantly, our results proved that pTK-IL15 transfected T cells could be simply eliminated by GCV with no obvious side effects in vivo (Fig. 9) . In a word, this work shows potent effect of selectively expanded antigen-specific CD4 + T cells upon pTK-IL15 transfection and indicates that retrovirus-mediated IL-15 expression enhanced the feasibility and efficiency of adoptive CD4 + T cell therapy.
MATERIALS AND METHODS
Plasmid construction and retrovirus production
The full-length human IL15 gene was cloned by PCR from a plasmid obtained from InVivogene (San Diego, CA). The human IL15 gene encodes the isoform with a 48 AA signal peptide. Tgls (+)-hytk vector was a gift from the lab of Dr. Robert Overell. IL-15 and GFP gene were cloned into tgls (+)-hytk vector to acquire recombinant retrovirus vector pTK-IL15 through restriction site BamHI, while pTK-Con vector was taken as a control vector (Fig. 1A) . Retrovirus packaging vector pCL-10A1 was obtained from Imgenex (San Diego, CA) and is a MuLV-based vector. The retroviral supernatant was prepared as following. Briefly, 293T cells were cotransfected with pCL-10A1 and pTK-IL15/pTK-Con vectors using Lipofectamine 2000 (Invitrogen, San Diego, CA) in accordance with the manufacturer's instruction. The quantity of pTK-IL15/pTK-Con is 10% of pCL-10A1. And the stable retrovirus packaging cell clones were screened by 200 μg/mL hygromycin B (Roche, Indianapolis, IN) resistance. The supernatants containing retrovirus were collected and infiltrated (0.45 μm pore size, Millipore, Bedford, MA).
Mice and tumor models
All mice were maintained in a specific pathogen-free environment at the Institute of Biophysics, Chinese Academy of Sciences, Beijing. Sex and age-matched mice were used with the approval of appropriate authorities. The wild type BALB/c mice were purchased from Weitonglihua. For adoptive T cell transfer experiments, tumor cells were s.c. inoculated at the flank of BALB/c mice, at 2.5 × 10 6 J558L-mOva or 
Preparation of antigen-presenting cells
Splenocytes were isolated from the spleen of wild type BALB/c mice.
The fresh working solution of 25 μg/mL mitomycin C was prepared in culture medium. 1 × 10 7 splenocytes were treated in 500 μL mitomycin C working solution for 30 min at 37°C.
Generation and transduction of CD4 + T cells
Do11.10 CD4 + T cells which recognized OVA peptide 323-329 were purified from the spleen of Do11.10 mice (Jackson Laboratory, Maine, USA) using CD4 beads (Miltenyi Biotec, Heidelberg, Germany). For transfection, these T cells were plated at 2 × 10 6 cell/well in 24-well plates and stimulated with Ova 323-339 peptide pulsed 1 × 10 7 APC/ well (antigen-presenting cells) for 2 days. Then the proliferating T cells were incubated with retroviral supernatants for 6 h. Then the transfected CD4 + T cells were incubated in 10 ng/mL recombinant hIL-2 or 50 ng/mL recombinant hIL-15 (R&D system, Minneapolis, MN). The release of IL-15 by control and transfected CD4 + T cells was measured in the culture supernatant by specific ELISAs (BD Biosciences, Franklin Lakes, NJ). ] thymidine (Perkinelmer, Waltham, MA) was added and incubated during the last 18 h in a 5% CO 2 humidified atmosphere at 37°C. After washing the cells twice with cold PBS, the cells were counted in a scintillation counter (Perkinelmer). Each concentration point was repeated in triplicate wells, and at least three independent experiments were performed. The results are expressed as the standard error of the mean.
Enzyme-linked immunospot assay
Cytokine concentrations in culture supernatants were measured using a human IL-15 ELISA kit (BD Bioscience, Franklin Lakes, NJ) in accordance with the manufacturer's instructions.
Western blot analysis
The protein samples were run on sodium dodecyl sulfate (SDS)-10% polyacrylamide gels and transferred to nitrocellulose membranes. The membrane was blocked in Superblock blocking buffer, incubated with the appropriate antibody and subsequently incubated with a secondary antibody conjugated to horseradish peroxidase. The immunoreactive bands were visualized with an ECL system (BioRad, Hercules, CA).
Determination of transgenic CD4
+ T cells in vivo BALB/c mice were treated with 0.8 mg/mL BrdU (Sigma-Aldrich, San Diego, CA) in their drinking water as described before (Judge et al., 2002) . BrdU solution was prepared in sterile water, protected from light exposure, and changed daily. During the continuous labeling phase, BALB/c mice infused with IL-15 transfected CD4 + T cells received BrdU up to 3 days. As a control, BALB/c mice infused with pTK-Con transfected CD4 + T cells were treated with BrdU in parallel.
On the day of the assay, splenocytes or tumor-infiltrated lymphocytes from these mice were used as positive BrdU staining control. BrdU intracellular staining was performed. In each staining experiment, Percp-CD4 and FITC-KJ26 were used to define the transferred CD4 + T cells.
Validation of the suicide gene thymidine kinase
To evaluate the functionality of the suicide gene, mice bearing the IL-15 transfected with hytk vector were treated with 50 mg/kg GCV every day for 3 days. The GCV treatment was initiated 1 day after adoptive immunotherapy. The percentage of transferred CD4 + T cell was detected by fluorescence-activated cell sorting (FACS).
Statistical analysis
The data were analyzed using Fisher's exact test and two-tailed unpaired Student's t-test. Means ± SD are presented. p < 0.05 was considered statistically significant.
